iStent Inject in phakic open-angle glaucoma

Session Details

Session Title: Glaucoma II

Session Date/Time: Tuesday 08/09/2015 | 08:00-10:30

Paper Time: 08:12

Venue: Room 17

First Author: : M.Klamann GERMANY

Co Author(s): :    J. Gonnermann   M. Pahlitzsch   A. Maier   N. Torun   E. Bertelmann        

Abstract Details

Purpose:

The effectiveness and complication profile of the iStent inject implantation among different phakic open angle glaucoma subgroups were analyzed.

Setting:

Department of Ophthalmology, University Medicine Charité Berlin, Berlin, Germany.

Methods:

In this retrospective cohort outcome study, 32 consecutive phakic patients suffering from glaucoma (primary open angle glaucoma (POAG) N = 17; pseudoexfoliation glaucoma (PEX) N = 15) were treated with the iStent inject. The intraocular pressure (IOP) and the number of antiglaucoma medication before and after surgery were evaluated.

Results:

In POAG, mean IOP at 6 months measured 14.19 ± 1.38 mmHg with an average decrease of 33% from preoperative IOP (p<0.001), and 15.33 ± 1.07 mmHg with an average decrease of 35% in PEX (p<0.001), respectively. The number of antiglaucoma medication significantly decreased from 2.19 ± 0.91 to 0.88 ± 0.62 in POAG (p<0.001) and from 2.33 ± 1.23 to 1.04 ± 0.30 in PEX (p<0.001) after 6 months

Conclusions:

In conclusion, implantation of the iStent inject has the ability to lower the postoperative IOP significantly in phakic POAG and PEX after a short follow-up of 6 months with a favorable risk profile.

Financial Interest:

NONE